Literature DB >> 19955220

The effects of VEGF-R1 and VEGF-R2 ligands on angiogenic responses and left ventricular function in mice.

Jenni Huusko1, Mari Merentie, Marike H Dijkstra, Minttu-Maria Ryhänen, Henna Karvinen, Tuomas T Rissanen, Maarten Vanwildemeersch, Marja Hedman, Jukka Lipponen, Suvi E Heinonen, Ulf Eriksson, Masabumi Shibuya, Seppo Ylä-Herttuala.   

Abstract

AIMS: Vascular endothelial growth factors (VEGFs) and their receptors (VEGF-Rs) are among the most powerful factors regulating vascular growth. However, it has remained unknown whether stimulation of VEGF-R1, VEGF-R2 or both of the receptors produces the best angiogenic responses in myocardium. The aim of this study was to compare the VEGF-R1-specific ligand VEGF-B(186), VEGF-R2-specific ligand VEGF-E and VEGF-A(165,) which stimulates both receptors, regarding their effects on angiogenesis and left ventricular function in mice. METHODS AND
RESULTS: High-resolution echocardiography was used to guide the closed-chest injections of adenoviral (Ad) vectors expressing VEGF-B(186,) VEGF-E, and VEGF-A(165) into the anterior wall of the left ventricle in C57Bl/6J mice. Angiogenic and functional effects were analysed using histology, ultrasound and perfusion analyses 6 (D6) and 14 (D14) days after the Ad injection. AdVEGF-A(165) induced a strong angiogenic response seen as an enlargement of myocardial capillaries whereas angiogenesis induced by AdVEGF-B(186) and AdVEGF-E seemed more physiological. The increase in the capillary area was accompanied with an increase in myocardial perfusion at D6 after the gene injection. AdVEGF-A(165) and AdVEGF-E induced endothelial-specific proliferation whereas AdVEGF-B(186) mostly induced proliferation of cardiomyocytes. AdVEGF-A(165) induced more pronounced tissue damage than AdVEGF-B(186) and AdVEGF-E. Left ventricular function measured as ejection fraction did not change during the follow-up. AdVEGF-A(165) increased both VEGF-R1 and VEGF-R2 protein expression whereas AdVEGF-B(186) and AdVEGF-E did not affect endogenous receptor expression levels.
CONCLUSION: AdVEGF-B(186) and AdVEGF-E are equally potent in inducing therapeutic angiogenesis in mouse myocardium and produce less side effects than AdVEGF-A(165).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19955220     DOI: 10.1093/cvr/cvp382

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  23 in total

1.  Adenoviral short hairpin RNA therapy targeting phosphodiesterase 5a relieves cardiac remodeling and dysfunction following myocardial infarction.

Authors:  Longhu Li; Husnain Kh Haider; Linlin Wang; Gang Lu; Muhammad Ashraf
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-23       Impact factor: 4.733

2.  VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection.

Authors:  Markus Räsänen; Joni Degerman; Tuuli A Nissinen; Ilkka Miinalainen; Risto Kerkelä; Antti Siltanen; Janne T Backman; Eero Mervaala; Juha J Hulmi; Riikka Kivelä; Kari Alitalo
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

Review 3.  The Biology of Hemodialysis Vascular Access Failure.

Authors:  Akshaar Brahmbhatt; Sanjay Misra
Journal:  Semin Intervent Radiol       Date:  2016-03       Impact factor: 1.513

4.  Acute myocardial rescue with endogenous endothelial progenitor cell therapy.

Authors:  Pavan Atluri; Corinna M Panlilio; George P Liao; William Hiesinger; David Andrew Harris; Ryan C McCormick; Jeffrey E Cohen; Tao Jin; Wei Feng; Rebecca D Levit; Nianguo Dong; Y Joseph Woo
Journal:  Heart Lung Circ       Date:  2010-08-16       Impact factor: 2.975

Review 5.  Endothelial fatty acid transport: role of vascular endothelial growth factor B.

Authors:  Carolina Hagberg; Annika Mehlem; Annelie Falkevall; Lars Muhl; Ulf Eriksson
Journal:  Physiology (Bethesda)       Date:  2013-03

6.  Efficacy and safety of myocardial gene transfer of adenovirus, adeno-associated virus and lentivirus vectors in the mouse heart.

Authors:  M Merentie; L Lottonen-Raikaslehto; V Parviainen; J Huusko; S Pikkarainen; M Mendel; N Laham-Karam; V Kärjä; R Rissanen; M Hedman; S Ylä-Herttuala
Journal:  Gene Ther       Date:  2015-12-24       Impact factor: 5.250

7.  AAV9-mediated VEGF-B gene transfer improves systolic function in progressive left ventricular hypertrophy.

Authors:  Jenni Huusko; Line Lottonen; Mari Merentie; Erika Gurzeler; Andrey Anisimov; Atsushi Miyanohara; Kari Alitalo; Pasi Tavi; Seppo Ylä-Herttuala
Journal:  Mol Ther       Date:  2012-10-23       Impact factor: 11.454

8.  Left ventricular dysfunction with reduced functional cardiac reserve in diabetic and non-diabetic LDL-receptor deficient apolipoprotein B100-only mice.

Authors:  Suvi E Heinonen; Mari Merentie; Marja Hedman; Petri I Mäkinen; Elina Loponen; Ivana Kholová; Fatima Bosch; Markku Laakso; Seppo Ylä-Herttuala
Journal:  Cardiovasc Diabetol       Date:  2011-06-30       Impact factor: 9.951

9.  Intracardiac injection of a capsid-modified Ad5/35 results in decreased heart toxicity when compared to standard Ad5.

Authors:  Raine Toivonen; Juha Koskenvuo; Mari Merentie; Mirva Söderström; Seppo Ylä-Herttuala; Mikko Savontaus
Journal:  Virol J       Date:  2012-11-29       Impact factor: 4.099

10.  Lack of cardiac and high-fat diet induced metabolic phenotypes in two independent strains of Vegf-b knockout mice.

Authors:  M H Dijkstra; E Pirinen; J Huusko; R Kivelä; D Schenkwein; K Alitalo; S Ylä-Herttuala
Journal:  Sci Rep       Date:  2014-08-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.